However, a number of different strategies targeting several aspects of the tau-dependent pathogenesis are being actively pursued at present, some already in advanced clinical development [12,13,14], thus broadening our range of potentially useful therapeutic tools to treat AD and other tauopathies. Here, MAPT is linked to Alzheimer disease.